Chugai assigns Vesanoid rights to Fuji Pharma in Japan

2 September 2016

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has agreed to transfer the rights to Fuji Pharma (TYO: 4554) for the manufacture and market Vesanoid (tretinoin)10mg in Japan for the indication of acute promyelocytic leukemia (APL), effective on November 1, 2016.

Vesanoid is an orally available vitamin A derivative for the treatment of APL developed by Swiss pharma giant Roche (ROG: SIX), which is the majority shareholder of Chugai. In Japan, Vesanoid was designated as orphan drug by the Minister of Health, Labor and Welfare, in 1993 and has been on the market since March 1995.

In order to ensure the constant supply of Vesanoid, Chugai continues to distribute the product in the interim. Once all Chugai labeled products have been sold to the market, the distribution of Fuji Pharma labeled products will be implemented.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK